|
1
|
Chapman R, van Diepen M, Douglass N, Galant S, Jaffer M, Margolin E, Ximba P, Hermanus T, Moore PL, Williamson AL. Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV. Vaccines (Basel) 2021; 9:1281. [PMID: 34835214 PMCID: PMC8620012 DOI: 10.3390/vaccines9111281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 10/18/2021] [Accepted: 10/27/2021] [Indexed: 11/18/2022] Open
Abstract
The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.
Collapse
Affiliation(s)
- Ros Chapman
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Michiel van Diepen
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Nicola Douglass
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Shireen Galant
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Mohamed Jaffer
- Electron Microscope Unit, University of Cape Town, Rondebosch 7701, South Africa;
| | - Emmanuel Margolin
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Phindile Ximba
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| | - Tandile Hermanus
- Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; (T.H.); (P.L.M.)
- Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa
| | - Penny L. Moore
- Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; (T.H.); (P.L.M.)
- Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Congella, Durban 4013, South Africa
| | - Anna-Lise Williamson
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa; (M.v.D.); (N.D.); (S.G.); (E.M.); (P.X.); (A.-L.W.)
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa
| |
Collapse
|